このエントリーをはてなブックマークに追加
ID 65097
FullText URL
Author
Otani, Yoshihiro Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Satomi, Kaishi Department of Pathology, Kyorin University School of Medicine
Suruga, Yasuki Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Ishida, Joji Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Fujii, Kentaro Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Ichimura, Koichi Department of Brain Disease Translational Research, Graduate School of Medicine, Juntendo University
Date, Isao Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences ORCID Kaken ID publons researchmap
Abstract
Despite the current progress of treatment, pediatric-type diffuse glioma is one of the most lethal primary malignant tumors in the central nervous system (CNS). Since pediatric-type CNS tumors are rare disease entities and highly heterogeneous, the diagnosis is challenging. An accurate diagnosis is essential for the choice of optimal treatment, which leads to precision oncology and improvement of the patient’s outcome. Genome-wide DNA methylation profiling recently emerged as one of the most important tools for the diagnosis of CNS tumors, and the utility of this novel assay has been reported in both pediatric and adult patients. In the current World Health Organization classification published in 2021, several new entities are recognized in pediatric-type diffuse gliomas, some of which require methylation profiling. In this review, we investigated the utility of genome-wide DNA methylation profiling in pediatric-type diffuse glioma, as well as issues in clinical application of this assay. Furthermore, the combination of genome-wide DNA methylation profiling and other comprehensive genomic assays, which may improve diagnostic accuracy and detection of the actionable target, will be discussed.
Keywords
Genome-wide DNA methylation profiling
pediatric-type diffuse glioma
pediatric brain tumor
Note
This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s10014-023-00457-6
This fulltext file will be available in Apr. 2024.
Published Date
2023-04-01
Publication Title
Brain Tumor Pathology
Volume
volume40
Issue
issue2
Publisher
Springer Science and Business Media LLC
Start Page
56
End Page
65
ISSN
1433-7398
NCID
AA11203151
Content Type
Journal Article
language
English
OAI-PMH Set
岡山大学
Copyright Holders
© The Author(s), under exclusive licence to The Japan Society of Brain Tumor Pathology 2023
File Version
author
PubMed ID
DOI
Web of Science KeyUT
Related Url
isVersionOf https://doi.org/10.1007/s10014-023-00457-6
Citation
Otani, Y., Satomi, K., Suruga, Y. et al. Utility of genome-wide DNA methylation profiling for pediatric-type diffuse gliomas. Brain Tumor Pathol 40, 56–65 (2023). https://doi.org/10.1007/s10014-023-00457-6
Funder Name
Ministry of Education, Culture, Sports, Science and Technology
助成番号
21K20803
22K16687